Furthermore, by re-analysis of the public monocytic melanoma dataset GSE120575, we found that patients who did not respond to PD-1/CTLA4 inhibitors had higher SIRPα expression on monocyte/macrophage cells (Fig. 5C). This evidence concerns the gene CTLA4 and melanoma.